Adam Levy
Investor Relations Contact en ALAUNOS THERAPEUTICS, INC. .
Perfil
Adam D.
Levy is currently the Executive Director-Investor Relations at Gilead Sciences, Inc., the Director at Vesselon, Inc., the Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc., the EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc., and the SVP, Head-Investor Relations & Corporate Affairs at Acrivon Therapeutics, Inc. Previously, he worked as the Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc. Dr. Levy completed his undergraduate and doctorate degrees at the University of Illinois and holds an MBA from the Kellogg School of Management.
Cargos activos de Adam Levy
| Empresas | Cargo | Inicio |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Investor Relations Contact | 01/11/2020 |
| TURG POIN | Investor Relations Contact | 08/11/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
| ACRIVON THERAPEUTICS, INC. | Investor Relations Contact | 20/07/2023 |
Vesselon, Inc.
 Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Director/Board Member | - |
Antiguos cargos conocidos de Adam Levy.
| Empresas | Cargo | Fin |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Formación de Adam Levy.
| University of Illinois | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Health Technology |
- Bolsa de valores
- Insiders
- Adam Levy
